Dermata Therapeutics pivots to DTC skincare; reports year-end 2025 cash of $7.5M

Dermata Therapeutics, Inc.

Strategic pivot from prescription derm to direct-to-consumer skincare brand Tome; first product launch mid-2026.
Cash and equivalents $7.5M at Dec 31, 2025 ($3.2M prior year); funded into Q1 2027.
Raised $15.4M gross in 2025/early 2026 including $4.125M private placement with insider participation.
R&D expenses fell to $2.9M from $8.2M as STAR-1 acne study completed; SG&A up to $4.8M on marketing.
Hired Kyra Peckaitis as VP Marketing; withdrew XYNGARI IND despite positive Phase 3 data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.84

Dermata Therapeutics, Inc. reported financial results for year ended December 31, 2025.

Period: year ended December 31, 2025
Result: reported results

Exact text from the filing

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-012991

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.